| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | November 8, 2024 4:30 P.M. |
| Form: | F-3 | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | November 8, 2024 4:30 P.M. |
| Form: | F-3 | ||||||
| |||||||
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/12/2022 | $6.00 | Buy | H.C. Wainwright |
| 10/10/2022 | $9.00 → $2.00 | Buy → Hold | Stifel |
| 8/18/2022 | Overweight | Wells Fargo | |
| 3/31/2022 | $7.00 | Overweight | Piper Sandler |
| 2/23/2022 | $12.00 | Overweight | Cantor Fitzgerald |
| 10/21/2021 | $10.00 | Buy | Truist |
| 10/12/2021 | $13.00 → $12.00 | Outperform | SVB Leerink |
| 9/30/2021 | $12.00 | Buy | Stifel |
EFFECT - Affimed N.V. (0001608390) (Filer)
424B5 - Affimed N.V. (0001608390) (Filer)
F-3 - Affimed N.V. (0001608390) (Filer)
Laidlaw & Co. analyst Yale Jen maintains Affimed (NASDAQ:AFMD) with a Buy and raises the price target from $15 to $25.
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Affimed (NASDAQ:AFMD) with a Buy and maintains $10 price target.
H.C. Wainwright initiated coverage of Affimed Therapeutics with a rating of Buy and set a new price target of $6.00
Stifel downgraded Affimed Therapeutics from Buy to Hold and set a new price target of $2.00 from $9.00 previously
Wells Fargo resumed coverage of Affimed Therapeutics with a rating of Overweight
MANNHEIM, Germany, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed" or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that Shawn M. Leland, PharmD, RPh has been appointed as Chief Executive Officer (CEO). Dr. Andreas Harstrick, who has been serving as acting CEO since January 2024 will continue in his position as Chief Medical Officer (CMO). Shawn is an accomplished pharmaceutical and biotechnology professional with more than 15 years of experience in the industry. He has a proven track record in successfully advancing the development of novel oncology assets, rais
HEIDELBERG, Germany, June 22, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the appointment of Dr. Constanze Ulmer-Eilfort to its Supervisory Board. Dr. Ulmer-Eilfort's appointment was approved during the Annual General Meeting of Shareholders which took place on June 21, 2023. "We are delighted to announce the appointment of Dr. Ulmer-Eilfort to our Supervisory Board," said Dr. Thomas Hecht, Chairman of Affimed's Supervisory Board. "Constanze brings a wealth of legal expertise and a deep understanding of the biotech and he
HEIDELBERG, Germany, June 16, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced the appointment of Ms. Uta Kemmerich-Keil as director on its Supervisory Board effective immediately. The appointment was approved during the Annual General Meeting of Shareholders on June 15, 2021. "We are pleased to welcome Uta to Affimed's Supervisory Board," said Dr. Thomas Hecht, Chairman of the Supervisory Board. "Uta brings unique and very deep and extensive executive experience in the life sciences industry. With over 20 years of leadership roles in driving higher busine
SC 13G - Affimed N.V. (0001608390) (Subject)
SC 13G/A - Affimed N.V. (0001608390) (Subject)
SC 13G/A - Affimed N.V. (0001608390) (Subject)
MANNHEIM, Germany, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release third quarter 2024 results and corporate update on Thursday, November 14, 2024. The Company will host a conference call at 8:30 a.m. EST / 14:30 CET. The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the "Webcasts" section on the "Investors" page of the Affimed website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. To access the call by phone, please use link https://r
AFM24 combination with atezolizumab: 24 patients treated in the EGFR mutant (EGFRmut) non-small cell lung cancer (NSCLC) cohort; in 17 response-evaluable patients: 1 complete response (CR), 3 partial responses (PRs) and 8 stable diseases (SDs) were reported. Objective response rate (ORR) is 23.5% (4/17) and disease control rate (DCR) is 70.6% (12/17). Median follow-up of > 7 months, 8 of 17 patients continue on treatment.The EGFR wild type (EGFRwt) cohort of treatment refractory NSCLC patients has treated 40 patients; ORR and safety data is expected in Q4 2024 Acimtamig (AFM13) combination with AlloNK® (AB-101): Enrollment for relapsed/refractory (r/r) Hodgkin Lymphoma (HL) patients in cohor
MANNHEIM, Germany, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release second quarter 2024 results and corporate update on Thursday, September 5, 2024. The Company will host a conference call at 8:30 a.m. EDT / 14:30 CET. The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the "Webcasts" section on the "Investors" page of the Affimed website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. To access the call by phone, please use linkhttps://r
MANNHEIM, Germany, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will release third quarter 2024 results and corporate update on Thursday, November 14, 2024. The Company will host a conference call at 8:30 a.m. EST / 14:30 CET. The conference call will be available via phone and webcast. The live audio webcast of the call will be available in the "Webcasts" section on the "Investors" page of the Affimed website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. To access the call by phone, please use link https://r
MANNHEIM, Germany, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced three abstracts on two of its innate cell engagers (ICE®) are accepted for presentation at the 66th ASH Annual Meeting and Exposition taking place December 7-10, 2024, in San Diego, California. An oral presentation will feature clinical results including promising efficacy and safety data from the AFM28 phase 1 dose escalation study in relapsed/refractory acute myeloid leukemia (AML). A poster with preclinical data will highlight the in vitro efficacy of
MANNHEIM, Germany, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (NASDAQ:AFMD) ("Affimed", or the "Company"), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Executive Officer, Shawn M. Leland, PharmD, RPh, will participate in a fireside chat at the Cantor Global Healthcare Conference 2024 on Tuesday, September 17, 2024 at 8:00 a.m. Eastern Daylight Time / 14:00 Central European Time. A live webcast of the presentation will be accessible on Affimed's website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. A replay of the call will be archived on Affimed's website fo